• PF-562271 HCl: Precision FAK/Pyk2 Inhibition in Tumor Resear

  2026-06-27

  PF-562271 HCl from APExBIO offers unparalleled selectivity and potency for dissecting focal adhesion kinase signaling in advanced cancer models. This guide delivers workflow-optimized protocols, comparative insights, and troubleshooting tips to accelerate translational discoveries in tumor growth inhibition and microenvironment modulation.

• Silymarin: Verified Milk Thistle Extract for Oxidative Stres

  2026-06-26

  Silymarin, a polyphenolic flavonolignan complex from milk thistle, is a well-characterized tool for oxidative stress, cancer, and antiviral research. Its reproducible in vitro activity and defined solubility profile enable robust experimental design. Recent advances clarify its mechanism and boundaries in preclinical models.

• L1023 Anti-Cancer Compound Library: High-Throughput Oncology

  2026-06-26

  The L1023 Anti-Cancer Compound Library by APExBIO empowers cancer researchers with 1,164 rigorously validated compounds, targeting pivotal oncogenic pathways for high-throughput screening. Discover how streamlined protocols, advanced assay integration, and troubleshooting insights accelerate precision oncology breakthroughs.

• ATM Inhibition Promotes Macropinocytosis and Metabolic Adapt

  2026-06-25

  This study uncovers how inhibiting ATM kinase induces macropinocytosis, aiding cancer cell survival in nutrient-poor environments. The findings reveal a metabolic vulnerability in ATM-inhibited tumors, with implications for targeting nutrient uptake pathways in cancer therapy research.

• Perphenazine as a Dopamine D2 Receptor Antagonist in Host-Di

  2026-06-25

  Perphenazine is redefining the research landscape, offering dual value as a dopamine D2 receptor antagonist and a tool for host-directed antibacterial strategies. Explore optimized workflows, troubleshooting insights, and protocol parameters for advanced neuropharmacology and infection models.

• Perospirone (SM-9018 freebase): Assay Reliability for Neurop

  2026-06-24

  This article addresses common experimental challenges in cell-based neuropsychiatric and cardiovascular assays, demonstrating how Perospirone (SM-9018 freebase) (SKU BA5009) from APExBIO enhances reproducibility, specificity, and mechanistic clarity. Evidence-backed insights and scenario-driven Q&A guide researchers in optimizing protocols and interpreting data when leveraging this compound’s unique receptor and ion channel profile.

• Perospirone Inhibits Vascular Kv1.5 Channels: Cardiovascular

  2026-06-23

  The reference study reveals that Perospirone (SM-9018 free base), beyond its known serotonergic and dopaminergic receptor activity, directly inhibits vascular Kv1.5 channels in coronary arterial smooth muscle cells. This previously unrecognized off-target effect suggests new considerations for both neuropsychiatric and cardiovascular research models using this atypical antipsychotic.

• Olsalazine Sodium: Mechanistic Leverage for Translational Re

  2026-06-23

  This thought-leadership article explores the mechanistic and strategic value of Olsalazine Sodium, a mesalamine dimer, for translational researchers working in colorectal cancer and inflammation. By dissecting its dual role as a potent LTB4 chemotaxis inhibitor and as a probe for xenobiotic transporter mechanisms, we contextualize experimental best practices, highlight workflow differentiators, and bridge findings from cancer biology to vector-borne disease research. The article uniquely elevates product intelligence with integrative protocol guidance and a forward-looking outlook on cross-domain applications.

• DPP9 Mutation Drives Infantile Hyperinflammation via Inflamm

  2026-06-22

  Wolf et al. identified a de novo DPP9 mutation as the cause of severe, infancy-onset hemophagocytic lymphohistiocytosis–like hyperinflammation. Their mechanistic work reveals that this DPP9 variant fails to restrain NLRP1 and CARD8 inflammasomes, resulting in uncontrolled cytokine production and autoinflammation. These insights refine our understanding of dipeptidyl peptidase regulation in immune homeostasis and highlight new experimental avenues for dissecting inflammasome-driven pathology.

• CHK1 Inhibition in Breast Cancer: Differential Roles by ER/P

  2026-06-22

  This study demonstrates that the effects of CHK1 inhibition in breast cancer are highly dependent on estrogen and progesterone receptor status, with distinct impacts on chemosensitivity and single-agent activity. These findings refine our understanding of targeted therapy strategies and highlight molecular heterogeneity as a key determinant in treatment response.

• Perospirone (SM-9018 Freebase): Mechanistic Insights and Res

  2026-06-21

  Perospirone (SM-9018 freebase) is a potent atypical antipsychotic with high-affinity antagonism at 5-HT2A and D2 receptors and partial 5-HT1A agonism. It is also a direct inhibitor of vascular Kv1.5 channels, opening new avenues in neuropsychiatric and cardiovascular research. This article clarifies its molecular actions, experimental parameters, and application boundaries.

• Perphenazine (SKU B6157): Reliable Dopamine D2 Antagonist fo

  2026-06-20

  This article explores real-world laboratory scenarios where Perphenazine (SKU B6157) delivers robust, reproducible results in cell viability, cytotoxicity, and host-pathogen research. By leveraging evidence-backed protocol parameters and APExBIO's rigorous quality controls, researchers can confidently address common assay challenges and advance neuropharmacology and immunology investigations.

• Perphenazine: Dopamine D2 Receptor Antagonist for Advanced R

  2026-06-19

  Perphenazine offers a unique dual advantage as a dopamine D2 receptor antagonist and immune modulator, making it indispensable for neuropharmacology and host-pathogen studies. This guide details optimized experimental workflows, troubleshooting strategies, and actionable insights from recent breakthroughs, positioning Perphenazine as a research powerhouse.

• Applied Workflows with Epidermal Growth Factor, Human Recomb

  2026-06-19

  Harness the power of recombinant human EGF for robust cell proliferation, migration, and mucosal healing studies. This guide delivers stepwise protocols, troubleshooting insights, and actionable integration of the latest chemogenetic findings, empowering researchers to optimize experimental precision with APExBIO’s validated EGF.

• Bacterial OMV-Based mRNA Display for Personalized Tumor Vacc

  2026-06-18

  Li et al. introduce a rapid, modular approach for surface display and delivery of mRNA antigens using genetically engineered bacterial outer membrane vesicles (OMVs). This strategy demonstrates significant tumor regression, immune memory induction, and a plug-and-display platform that may accelerate the development of personalized mRNA vaccines.

812 records 16/55 page Previous Next First page 上5页 1617181920 下5页 Last page